You are here: Industry Insights > gilead

News List

Gilead withdraws use of Zydelig to treat cancer ExpressPharma
January 17, 2022
The US FDA gave the drug an accelerated approval to treat relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic leukemia along with relapsed Chronic Lymphocytic Leukemia (CLL).
Gilead and AWS collaborate on development and delivery of new medicines for patients expresspharma
December 02, 2021
With AWS as its preferred cloud provider, Gilead uses AWS machine learning and analytics to better inform clinical trial design and advance data-driven decision making, while prioritising patient privacy and security...
Gilead and Merck collaborate for breast cancer combination treatment Pharmaceutical-Technology
November 01, 2021
Gilead Sciences and Merck (MSD) have signed a clinical trial partnership and supply agreement to assess the efficacy of the former’s Trodelvy (sacituzumab govitecan-hziy) along with...
Veklury Drives 2Q Growth for Gilead contractpharma
August 02, 2021
Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.
Gilead Sciences Announces Launch of Asia Pacific ALL4LIVER Grant 2021 prnasia
July 28, 2021
Gilead Sciences, Inc. today announced the launch of the 2021 Gilead Asia Pacific ALL4LIVER Grant, a new grant program to support local communities in strengthening liver disease education efforts across Asia Pacific.
More than Half of Singaporeans Unaware of Link between Viral Hepatitis and Liver Failure: Survey prnasia
July 28, 2021
The findings of a new survey, commissioned by Gilead Sciences, on Singaporeans' awareness, knowledge and attitudes towards liver health showed that more than half (58%) of the general population do not recognise that viral hepatitis can cause liver ...
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Opt drugs
July 08, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the FDA seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor.
Gilead seeks US approval for long-acting HIV drug lenacapavir pharmatimes
July 01, 2021
Gilead has filed its investigational long-acting HIV drug lenacapavir with the US Food and Drug Administration (FDA), seeking approval in patients with multi-drug resistant infection.
Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r) prnasia
June 18, 2021
Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®# (tenofovir alafenamide 25 mg, TAF) from ...
Manufacturing capacity of Remdesivir ramped up to around 1.19 cr crore vials a month: Govt expresspharma
May 19, 2021
The production capacity of remdesivir used for the treatment of COVID-19 has increased from 38 lakh vials per month to nearly 1.19 crore vials per month, the Ministry of Chemicals and Fertilizers said.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page